Based on the rationale that PIK3CA mutations may predict response to PI3K pathway inhibitors, breast, cervical, endometrial, and ovarian cancers were sequenced for the presence of activating PIK3CA mutations and treated with different allosteric mTOR inhibitors (i.e., rapalogs) or the PI3K inhibitor PX866 either as single agent or combination in a prospective phase I clinical trial. Here, PIK3CB is linked to ovarian carcinoma.